Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

The new injection, Nirsevimab, will be given to high-risk babies, including those born too early to be protected by the RSV ...

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

Nirsevimab Reduced Hospitalizations for Infants With RSV — Monoclonal antibody is highly effective, but in short supply by Katherine Kahn , Staff Writer, MedPage Today December 27, 2023 ...

Researchers also found that nirsevimab was 69.6% effective against RSV bronchiolitis leading to PICU admission (95% CI 42.9-83.8) and 67.2% effective against RSV-associated bronchiolitis requiring ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) infections among American Indian and Alaskan Native (AI/AN) infants, based ...

Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination's role in offering protection.